Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our medical information is accurate, up to date, and scientifically balanced.

DAURISMO™ (glasdegib)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our medical information is accurate, up to date, and scientifically balanced.

DAURISMO™ Quick Finder

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the...
Did you find an answer to your question? Yes No

WARNING: EMBRYO-FETAL TOXICITY

DAURISMO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. DAURISMO is embryotoxic, fetotoxic, and teratogenic in animals...

Did you find an answer to your question? Yes No

1 INDICATIONS AND USAGE

DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that...

Did you find an answer to your question? Yes No

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage and Schedule

The recommended dosage of DAURISMO is 100 mg orally once daily on days 1 to 28 in combination with...

Did you find an answer to your question? Yes No

3 DOSAGE FORMS AND STRENGTHS

DAURISMO 100 mg tablets: round, pale orange film-coated tablet debossed with "Pfizer" on one side and "GLS 100" on the other.

DAURISMO 25 mg tablets: round, yellow film-coated tablet...

Did you find an answer to your question? Yes No

4 CONTRAINDICATIONS

None.

Did you find an answer to your question? Yes No

5 WARNINGS AND PRECAUTIONS

5.1 Embryo-Fetal Toxicity

Based on its mechanism of action and findings from animal embryo-fetal developmental toxicity studies, DAURISMO...

Did you find an answer to your question? Yes No

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

QTc Interval Prolongation [see Warnings and...
Did you find an answer to your question? Yes No

7 DRUG INTERACTIONS

...
Table 5. Drug Interactions with DAURISMO
Did you find an answer to your question? Yes No

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on its mechanism...

Did you find an answer to your question? Yes No

10 OVERDOSAGE

There is no specific antidote for DAURISMO. Management of DAURISMO overdose should include symptomatic treatment and ECG monitoring.

Glasdegib has been administered in clinical studies up to a dose of 640...

Did you find an answer to your question? Yes No

11 DESCRIPTION

DAURISMO (glasdegib) is a hedgehog pathway inhibitor. It is formulated with the maleate salt of glasdegib. The molecular formula for glasdegib maleate is C25H26...

Did you find an answer to your question? Yes No

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Glasdegib is an inhibitor of the Hedgehog pathway. Glasdegib binds to and inhibits Smoothened, a transmembrane...

Did you find an answer to your question? Yes No

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity studies have not been performed with glasdegib.

Glasdegib...

Did you find an answer to your question? Yes No

14 CLINICAL STUDIES

The efficacy of DAURISMO in combination with low-dose cytarabine was evaluated in a multicenter, open-label, randomized study (Study BRIGHT AML 1003, NCT01546038) that included 115 patients age 55 years...

Did you find an answer to your question? Yes No

16 HOW SUPPLIED/STORAGE AND HANDLING

DAURISMO is supplied in the following strengths and package configurations:

...
Did you find an answer to your question? Yes No

This Medication Guide has been approved by the U.S. Food and Drug Administration.

...
Did you find an answer to your question? Yes No

This product's label may have been updated. For current full prescribing information, please visit www.DAURISMO.com.

...
Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event